Gilead Opts In On Multiple Arcus IO Candidates, Setting Up Combo Therapy Plans

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Gilead is licensing two anti-TIGIT candidates and a pair of adenosine pathway-targeted drugs. The firms will study various IO combo regimens, possibly including Gilead drugs like Trodelvy.

Instagram style filter silhouette of a successful woman or girl arms raised celebrating at sunrise or sunset in front of the New York City Skyline
Arcus gets validation with Gilead opting in early on multiple IO candidates

Gilead Sciences, Inc. has elected to take three options under its May 2020 immuno-oncology collaboration with Arcus Biosciences, Inc., updating the deal in a way that will bring Arcus $725m in option fees and give Gilead the ability to explore multiple IO combinations, including ones that may include its own drugs and investigational candidates, such as its breast cancer therapy Trodelvy (sacituzumab govitecan).

“The early options by Gilead also enable us to access and benefit from the clinical, commercial and global resources of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.